(-0.07%) 5 143.25 points
(-0.02%) 38 551 points
(-0.02%) 17 901 points
(-0.22%) $82.45
(1.87%) $2.07
(-1.01%) $2 334.00
(-1.99%) $27.11
(-0.48%) $956.90
(0.19%) $0.934
(0.35%) $11.02
(0.25%) $0.798
(-0.22%) $93.10
2 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.42%
-0.50% $ 44.02
@ $45.58
Emitido: 14 feb 2024 @ 15:47
Retorno: -3.41%
Señal anterior: feb 14 - 09:30
Señal anterior:
Retorno: 2.09 %
Live Chart Being Loaded With Signals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...
Stats | |
---|---|
Volumen de hoy | 552 586 |
Volumen promedio | 696 204 |
Capitalización de mercado | 3.62B |
EPS | $0 ( 2024-02-15 ) |
Próxima fecha de ganancias | ( $-1.730 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.34 |
ATR14 | $0.0330 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Crombez Eric | Sell | 142 | Common Stock |
2024-04-16 | Huizenga Theodore Alan | Sell | 14 | Common Stock |
2024-03-11 | Kassberg Thomas Richard | Sell | 11 509 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 550 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 145 | Common Stock |
INSIDER POWER |
---|
45.65 |
Last 99 transactions |
Buy: 915 632 | Sell: 371 334 |
Volumen Correlación
Ultragenyx Pharmaceutical Correlación
10 Correlaciones Más Positivas | |
---|---|
GAINL | 0.862 |
ITMR | 0.852 |
DVCR | 0.847 |
AVEO | 0.845 |
ISNS | 0.842 |
VLYPP | 0.831 |
CHMA | 0.825 |
OPNT | 0.825 |
SUMR | 0.813 |
EDUT | 0.813 |
10 Correlaciones Más Negativas | |
---|---|
SHSP | -0.9 |
BOCH | -0.891 |
XFOR | -0.833 |
GRCL | -0.833 |
ENPH | -0.827 |
RDHL | -0.82 |
THTX | -0.819 |
PTPI | -0.805 |
QTEK | -0.801 |
BLU | -0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ultragenyx Pharmaceutical Correlación - Moneda/Commodity
Ultragenyx Pharmaceutical Finanzas
Annual | 2023 |
Ingresos: | $434.25M |
Beneficio Bruto: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2023 |
Ingresos: | $434.25M |
Beneficio Bruto: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2022 |
Ingresos: | $363.33M |
Beneficio Bruto: | $335.01M (92.21 %) |
EPS: | $-10.12 |
FY | 2021 |
Ingresos: | $351.41M |
Beneficio Bruto: | $335.40M (95.44 %) |
EPS: | $-6.70 |
Financial Reports:
No articles found.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico